QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-15b

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...

 london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents

Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...

 heartburn-drug-zantac-litigation-gsk-and-other-pharma-giants-face-trial-over-cancer-claims

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to...

 amazon-web-services-focuses-on-the-future-anticipating-ai-challenges-years-in-advance-to-deliver-true-value-for-customers

Amazon is taking an all-encompassing approach to enterprise AI in an effort to better deliver the tools that customers need whe...

 cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.

Core News & Articles

- Bloomberg

Core News & Articles

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...

 cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-negative-for-gsk

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is app...

 whats-going-on-with-pfizer-shares-wednesday

Pfizer Inc. (NYSE: PFE) is experiencing notable stock movement on Wednesday afternoon. Here's what you need to know.

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 pfizer-reports-15-decrease-in-patient-enrollment-in-phase-3-ulcerative-colitis-trial-enrollment-drops-from-912-to-772-patients-trial-active-but-not-recruiting-primary-completion-date-revised-to-july-20-2026

https://clinicaltrials.gov/study/NCT03950232

 why-is-moderna-stock-trading-lower-on-wednesday

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...

 cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.